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Background: Polycystic ovary syndrome (PCOS) patients are at increased risk of pregnancy complications, which
may impair pregnancy outcome. Transfer of fresh embryos after superovulation may lead to abnormal implantation
and placentation and further increase risk for pregnancy loss and complications. Some preliminary data suggest
that elective embryo cryopreservation followed by frozen–thawed embryo transfer into a hormonally primed
endometrium could result in a higher clinical pregnancy rate than that achieved by fresh embryo transfer.
Methods/Design: This study is a multicenter, prospective, randomized controlled clinical trial (1:1 treatment ratio
of fresh vs. elective frozen embryo transfers).. A total of 1,180 infertile PCOS patients undergoing the first cycle of
in vitro fertilization (IVF) or intracytoplasmic sperm injection will be enrolled and randomized into two parallel groups.
Participants in group A will undergo fresh embryo transfer on day 3 after oocyte retrieval, and participants in
group B will undergo elective embryo cryopreservation after oocyte retrieval and frozen–thawed embryo transfer
in programmed cycles. The primary outcome is the live birth rate. Our study is powered at 80 to detect an
absolute difference of 10 at the significance level of 0.01 based on a two-sided test.
Discussion: We hypothesize that elective embryo cryopreservation and frozen–thawed embryo transfer will
reduce the incidence of pregnancy complications and increase the live birth rate in PCOS patients who need IVF
to achieve pregnancy.
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Polycystic ovary syndrome (PCOS) is the most common
cause of anovulatory infertility. Although more oocytes
than tubal infertile patients are retrieved from women
with PCOS during in vitro fertilization (IVF), similar preg-
nancy rates are achieved compared with tubal infertile
patients. Some data suggest that women with PCOS may
have increased miscarriage rates [1]. A previously reported
meta-analysis [2] demonstrated that PCOS patients are at
increased risk for pregnancy complications and neonatal
complications, including gestational diabetes, pregnancy-
induced hypertension, preeclampsia and preterm birth, all
of which may lower the chances of live births. Whether
that is attributed to the intrinsic characteristics of PCOS,
the underlying infertility, the disturbed steroids level or
a combination of these factors, however, is unclear [3].
Effective interventions are needed to improve pregnancy
outcomes in PCOS patients.
Additionally, both superovulation and assisted reproduct-
ive technologies may carry additional risks for abnormal
pregnancies. Multiple studies have reported higher risks of
abnormal placentation (such as greater placenta weight,
placenta previa and preeclampsia), pregnancy complications
(such as gestational hypertension) and obstetric complica-
tions (such as preterm delivery, low birth weight and high
cesarean section rate) in singleton pregnancies induced by
assisted conception compared with spontaneous conception
[3-6]. Researchers in several observational studies have
demonstrated that pregnancies arising from the transfer of
frozen–thawed embryos seem to have better obstetric and
perinatal outcomes (such as antepartum hemorrhage, small
for gestational age (SGA), low birth weight and perinatal
mortality) than those induced by fresh embryo transfer
[7-9]. Investigators in two independent studies revealed
a statistically significant association between elevated
peak serum estradiol (E2) levels on the day of the human
chorionic gonadotropin (hCG) trigger and the risks of
SGA and preeclampsia in singleton pregnancies conceived
via IVF [10,11]. Researchers in a cohort study [12] demon-
strated that elective cryopreservation of all embryos and
subsequent frozen–thawed embryo transfer reduced the
odds of SGA and preeclampsia compared with fresh
embryo transfer in patients with elevated peak serum
E2 levels (>3,450 pg/ml). We hypothesize that supra-
physiological steroid level immediately before embryo
implantation may represent an independent contribut-
ing factor to the increased risk of these pregnancy and
obstetric complications.
Unfortunately, most of the current evidence is based
on retrospective and uncontrolled studies in which the
results may have been confounded by the “second-best”
quality of embryos in frozen–thawed cycles. The primary
outcome of most existing studies is clinical pregnancy,
which is defined as the detection of a fetal heartbeat at7 weeks gestation. Furthermore, despite the distinct char-
acteristics of infertile PCOS patients compared with tubal
infertile patients, few long-term follow up studies have
been focused on PCOS patients undergoing IVF.
Methods/Design
In this multicenter, prospective, randomized controlled
clinical trial (1:1 treatment ratio), live birth rates of fresh
embryo transfer vs frozen–thawed embryo transfer are
being compared in 1,180 infertile PCOS patients under-
going their first cycle of IVF or intracytoplasmic sperm
injection (ICSI). Participants will be enrolled at 14 hospitals
across mainland China. This study has been approved by
the ethics committees at all study sites (listed in Additional
file 1). Informed consent will be obtained from each patient
before any study procedure is performed, in accordance
with good clinical practice. Reporting of the study results
will follow the 2010 revised CONSORT statement [13].
Participants
Inclusion criteria
The following are the inclusion criteria:
1. Women diagnosed with PCOS according to Chinese
PCOS diagnostic criteria
2. Women who have a ≥1-year history of infertility
3. Women ages ≥20 and <35 years old
4. Women who have at least one of the following
indications for IVF or ICSI:
a. Ovulation dysfunction and failure to become
pregnant after ovulation induction treatment
b. Tubal factors: unilateral or bilateral tubal
obstruction, adhesion, unilateral or bilateral
salpingectomy or tubal ligation
c. Male factors: oligoasthenozoospermia or
obstructive azoospermia
d. Women who are undergoing their first cycle of
IVF or ICSI
e. Women whose retrieved oocytes number more
than threeThe Chinese PCOS diagnostic criteria are menstrual
abnormality and either hyperandrogenism or PCO [14].
Menstrual disorders, including oligomenorrhea, amenor-
rhea or irregular uterine bleeding, are essential for the
diagnosis of PCOS. Oligomenorrhea is defined as spontan-
eous cycle length ≥35 days. Irregular uterine bleeding is
defined as spontaneous cycle length <21 days. Amenorrhea
is defined as spontaneous cycle length ≥6 months. Hyper-
androgenism is diagnosed on the basis of either hirsutism
or hyperandrogenemia. Hirsutism is determined by a
modified Ferriman–Gallwey score [15] >6 at the screening
examination. Hyperandrogenemia will be defined as an ele-
vated total testosterone level according to local laboratory
Shi et al. Trials 2014, 15:154 Page 3 of 6
http://www.trialsjournal.com/content/15/1/154criteria. Local cutoffs will be predetermined by each site
prior to study initiation. Polycystic ovarian syndrome is
defined as either an ovary that contains 12 or more folli-
cles measuring 2 to 9 mm in diameter or increased ovarian
volume (>10 cm3) [16]. Secondary causes of hyperandro-
genism and ovulation dysfunction will be excluded before
a PCOS diagnosis is confirmed, such as ovarian interstitial
tumor or adrenal tumor, congenital adrenal hyperplasia,
hyperprolactinemia and thyroid dysfunction.
Exclusion criteria
The following are the exclusion criteria:
1. Women who have undergone unilateral
oophorectomy
2. Women who have previously been diagnosed with a
uterine abnormality such as a malformed uterus
(uterus unicornis, septate uterus, duplex uterus or
uterus bicomis), adenomyosis, submucous myoma or
intrauterine adhesion
3. Women or their partners with an abnormal
chromosome karyotype not including chromosome
polymorphisms, which mainly refer to the variants
in the chromosomal heterochromatin region [17]
4. Women who have experienced recurrent
spontaneous abortions (including biochemical
pregnancy abortion), defined as three or more
previous pregnancy losses
5. Women with medical conditions that contraindicate
assisted reproductive technology and/or pregnancy,
such as poorly controlled type 1 or type 2 diabetes
mellitus; undiagnosed liver disease or dysfunction
(based on serum liver enzyme test results); renal
disease or abnormal serum renal function; significant
anemia; history of deep venous thrombosis,
pulmonary embolus or cerebrovascular accident;
uncontrolled hypertension or known symptomatic
heart disease; history of (or suspected) cervical
carcinoma, endometrial carcinoma or breast
carcinoma; and undiagnosed vaginal bleeding
6. Women who have developed severe ovarian
hyperstimulation syndrome (OHSS) during
controlled ovarian hyperstimulation (COH)
7. Women with retrieved oocytes numbering three or less
8. Women who are unable to comply with the study
procedures
Interventions
Qualified patients will be randomized into either of two
groups. Group A will undergo a fresh embryo transfer
after ovarian stimulation, and group B will have all of their
embryos cryopreserved after ovarian stimulation and then
undergo a frozen–thawed embryo transfer. All of the
participants will receive a standardized gonadotropin-releasing hormone (GnRH) antagonist ovarian stimulation
protocol and luteal phase support.
Controlled ovarian hyperstimulation and oocyte retrieval
The following list describes the COH and oocyte retrieval
protocol:
1. Baseline monitoring and initial dose determination:
Recombinant follicle-stimulating hormone (rFSH,
Gonal-f; Merck Serono, Geneva, Switzerland) will begin
on day 3 of spontaneous menses or cycle induced by
exogenous progesterone or oral contraceptive pills.
Baseline pelvic ultrasound and basal hormone
levels—that is, serum FSH, luteinizing hormone,
E2, progesterone and β-hCG test—will confirm an
early follicular phase milieu. The initiation doses
will be 112.5 IU/day for patients weighing ≤60 kg
and 150 IU/day for patients weighing >60 kg.
2. Ovarian response monitoring and rFSH dose
adjustment: At day 6 of ovarian stimulation,
transvaginal ultrasound scans and serum hormone
tests will be performed. rFSH doses will be adjusted
according to ovarian response. Afterward, such
monitoring will be performed either every other day
or every day. Human menopausal gonadotropin
(Menopur; Ferring Pharmaceuticals, St-Prex,
Switzerland) may be added if necessary [18,19].
3. GnRH antagonist starting time and dose: GnRH
antagonist (cetrorelix; Merck Serono, Darmstadt,
Germany) at a daily dose of 250 μg by subcutaneous
injection will begin when at least one follicle is ≥12 mm
in mean diameter until the trigger day (including the
trigger day).
4. hCG trigger for final oocyte maturation: hCG will be
administered at a dose of approximately 4,000 to
8,000 IU by intramuscular injection when at least
two follicles are ≥18 mm in mean diameter.
5. Transvaginal ultrasound-guided oocyte retrieval:
Oocyte retrieval will be performed 36 hours after
hCG injection.
On the oocyte retrieval day, qualified patients will be
randomized. For patients assigned to group A, luteal phase
support will be started just after follicular aspiration. For
patients assigned to group B, no luteal phase support will
be administered.
In vitro fertilization and embryo culture
The oocytes will be inseminated approximately 4 to 6 hours
after follicular aspiration. For the scoring of embryos at day
3, we will employ the Puissant et al. criteria, with a focus
on the number and regularity of blastomeres as well as the
percentage fragmentation [20]. Two embryos of top quality
will be marked for the first transfer cycle. For patients
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transferred on day 3, and the surplus embryos will been
frozen on day 3 or day 5 according to the routine followed
at different sites. For patients assigned to group B, all
embryos will be cryopreserved and at least two embryos of
top quality must be vitrified on day 3. To ensure that two
viable, thawed day 3 embryos will be transferred in subse-
quent programmed cycles, obtaining one or two extra day
3 frozen embryos will be suggested in case frozen embryos
lose their viability after thawing.
Embryo transfer and luteal phase support
Group A Participants in group A will receive luteal phase
support for 2 weeks with intramuscular progesterone
obtained on the oocyte retrieval day. On day 3 of embryo
culture, two embryos of top quality will be transferred
through a catheter using transabdominal ultrasound guid-
ance (full bladder). After embryo transfer, the patient will
lie in bed for 30 minutes. If the patient is pregnant, luteal
phase support will continue to 10 weeks gestation.
Group B On the third day of the second menstrual cycle
(either spontaneous or induced by giving progesterone
or oral contraceptive pills) after COH and oocyte retrieval,
patients in group B will receive oral E2 valerate (E2V) at a
dose of 4 mg daily. The E2V dose will remain unchanged
for 10 days and then will be increased to approximately
6 to 8 mg/day if endometrial thickness is still less than
8 mm. Intramuscular progesterone will be added when
endometrial thickness reaches ≥8 mm. Two frozen–
thawed embryos will be transferred on the fourth day
after progesterone initiation. The transfer procedure
will be the same as that used for the fresh embryo
transfer. E2V and progesterone will be continued at an
unchanged dose until the day on which serum β-hCG
levels are tested. If the patient is pregnant, luteal phase
support will continue until 10 weeks gestation.
Pregnancy evaluation
Serum β-hCG will be measured to determine pregnancy
14 days after embryo transfer. If a biochemical pregnancy
has been achieved, a transvaginal ultrasound scan will be
obtained 35 days after embryo transfer to evaluate the
clinical pregnancy. The ultrasound scan will be repeated
at 11 weeks gestation to confirm ongoing pregnancy if a
biochemical pregnancy has been achieved.
Follow-up evaluation
At 12 weeks gestation, the presence of first-trimester
pregnancy complications (OHSS, miscarriage, ectopic pre-
gnancy and/or gestational trophoblastic disease) will be
evaluated by inspecting medical records and will be re-
corded by completing the case report form for the first
pregnancy follow-up time point.At 28 weeks gestation, the second-trimester pregnancy
complications (prenatal diagnosis test results, abortion,
gestational diabetes, preeclampsia/eclampsia, incompetent
cervix, premature rupture of membrane and/or placenta
abruption) will be followed up by telephone call to com-
plete the second pregnancy follow-up time point.
At 37 weeks gestation, the third-trimester pregnancy
complications (preterm labor, placenta abruptio, placenta
accreta, placenta previa, preeclampsia/eclampsia, intrauter-
ine growth retardation, premature rupture of membrane
and/or abnormality of amniotic fluid) will be followed up
by telephone call to complete the third pregnancy follow-
up time point.
Participants will be required to notify investigators of
the time of delivery. An investigator will be sent to the
delivery hospital, and placental and cord blood samples
will be collected. The delivery information (gestational
age, delivery mode, placenta abnormality and/or delivery
complications), infant information (for example, birth
weight, birth defect) will be recorded by completing
forms designed for this fourth follow-up pregnancy visit.
The obstetric medical record will be copied, if possible,
for the study chart source documents.
At 6 weeks after delivery, postpartum information re-
garding complications of the mother (for example, postpar-
tum depression, infection, late postpartum hemorrhage)
and the infant (for example, neonatal respiratory distress
syndrome, neonatal jaundice, neonatal infection, neonatal
death, neonatal hospitalization) will be followed up by tele-
phone call for the fifth and final follow-up time point.
If a live birth is not achieved and there are surplus cryo-
preserved embryos from the first IVF cycle, we will track
the outcomes of all frozen embryo transfers in both groups
A and B.Randomization
Participants (N = 1,180) will be allocated randomly into one
of the two study groups at a ratio of 1:1. The allocation se-
quence will be generated by utilizing the ResMan Research
Manager central randomization clinical trial management
public platform (http://www.medresman.org/). The ran-
domization will be stratified by study site. On the day
of oocyte retrieval, investigators will log information into
the web database using user identifications and passwords
to obtain the randomization numbers and allocated groups
for the eligible patients. Both investigators and participants
will be aware of the allocations after oocyte retrieval.Outcome measurements
Primary outcome
The primary study endpoint is live birth, defined as
delivery of any viable infant ≥28 weeks gestation after
the first embryo transfer.
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Secondary efficacy parameters will include biochemical
pregnancy, clinical pregnancy, implantation rate and
ongoing pregnancy. Biochemical pregnancy will be
defined as a serum β-hCG level ≥10 IU/L 2 weeks after
embryo transfer. Clinical pregnancy will be defined as the
presence of intrauterine gestation sac at 7 weeks gestation.
Ongoing pregnancy will be defined as a viable pregnancy at
11 weeks gestation. Another secondary outcome will be
cumulative live birth results (with each woman having
only one allowable live birth) from the single IVF cycle.
The safety endpoints will include OHSS, miscarriage,
ectopic pregnancy, pregnancy complication, congenital
anomalies and neonatal complications.
Statistical analysis
Sample size and power calculations
Investigators in a recent study of Chinese infertile PCOS
patients undergoing conventional IVF or ICSI with fresh
embryo transfers reported that the live birth rate was
31.2 [21]. Imudia et al., in their cohort study reported a
live birth rate of 47.6 in cryothawed embryo transfer
cycles [12]. In their randomized trial comparing fresh
and frozen–thawed transfer in normal responders (average
age = 33 years), Shapiro et al. (2011) demonstrated that
the clinical pregnancy rate per transfer was 84.0 in the
cryopreservation group and 54.7 in the fresh embryo
transfer group. They reported that the ongoing pregnancy
rates per transfer (at 10 weeks gestation) for these two
groups were 78.0 and 50.9, respectively [22]. Shapiro et al.
also showed that the clinical pregnancy rates per transfer
in high responders were 79.6 in the cryopreservation
group and 65.4 in the fresh embryo transfer group. They
found that the ongoing pregnancy rates were 77.6% in the
cryopreservation group and 65.4 in the fresh embryo
transfer group [23]. In our present study, we plan to test
the primary hypothesis of a difference of 10 in the live
birth rate for the two randomization arms. Because all of
the participants in this study are under 35 years old, we
will assume that frozen–thawed embryo transfer will bring
about a live birth rate of 40 and fresh embryo transfer
will lead to a live birth rate of 30. A sample size of 530
prospectively enrolled participants in each randomization
arm will yield a statistical power of 80 at a significance
level of 0.01 to demonstrate an absolute difference in live
birth rates of 10 between treatment arms. Taking into
consideration a dropout rate of 10 (for example, due to
canceled cycles or elective cryopreservation of embryos
because of increased risk for OHSS), we will enroll 590
participants into each study group.
For the sample size calculations, the significance level
will be set at α = 0.01 and the statistical power will be
calculated as 1 − β = 0.80. The live birth rate in group A
will be set at 0.30. The live birth rate in group B willset at 0.40. The ratio between groups will be 1:1. The
minimum sample size will be 530 for each group, for a
total of 1,060 participants. Taking into consideration a
dropout rate of 10, we expect to ultimately have a total
of 1,180 enrollees, with 590 participants in each group.
Type of analysis
We will utilize an intent-to-treat approach to examine
differences in the live birth rates for first embryo transfer
cycle in the two treatment arms in the primary analysis
by the Pearson χ2 test. Safety parameters and secondary
efficacy parameters, such as pregnancy rate, OHSS rate
and other rates, will be analyzed using the Pearson χ2 test
and logistic regression (if necessary). Cox proportional
hazards models and the Kaplan-Meier method will be
applied to compare time to pregnancy and cumulative
live birth rates.
Trial status
The study was conceived and designed in 2011. The
first participant was randomized in June 2013. We
completed recruitment in April 2014, and patient follow-
up is ongoing.
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